Pfizer offshoot Zoetis lines up 'potential blockbuster' pet meds for Japan

Pharmaceuticals Pfizer offshoot Zoetis lines up 'potential blockbuster' pet meds for Japan More players enter growing market as domestic spending per animal rises The lifespans of cats and dogs are growing longer, leading to more spending on medicines and treatments. (Photo by Soichiro Ono) MAYUKO SUZUKI November 13, 2026 05:06 JST TOKYO -- The market for cancer and chronic illness treatments for pets is growing in Japan as household animals live longer lives, prompting companies such as U.S.-based Zoetis to launch new therapeutics here. Read Next Society Fatal dog attacks test Hong Kong's ambitions for a pet-friendly economy Life Vietnam's whale temples reveal secrets of the sea Travel & Leisure Japan's cat cafes find new ways to delight animal lovers Life Australian puppy yoga: It's a combination of cuddles and chaos Tea Leaves Japan horse racing finds a winning formula in the digital age Life From cafe owner to champion of Thailand's last dugongs Travel & Leisure Nara Park deer population sets record thanks to tourist generosity Datawatch Growth in species discoveries fuels hopes for new drugs Latest on Pharmaceuticals Pharmaceuticals Towa Pharmaceutical to ship Japan-made generics to US: CEO Pharmaceuticals Takeda bets on blockbuster drug trio to generate $11bn in peak sales Pharmaceuticals Takeda debuts narcolepsy drug targeting root cause, capping 15-year effort Sponsored Content About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.